Mission – To serve life scientists to achieve their mission faster
Vision – To be the most influential life sciences company for researchers worldwide
Strategy – To deliver sustainable, profitable, long-term growth



Our strategy is designed to generate sustainable sales and earnings growth and improved returns to shareholders. We have five strategic priorities:

to grow our core reagents business faster than the market;
establish new growth platforms;
scale organisation capabilities;
sustain attractive economics; and
selectively pursue partnerships and acquisitions

Abcam has a strong track record of executing on these priorities and has transitioned from being a small high growth company to being a significant player in our core markets, with future expansion potential through targeted investment. Abcam is the market leader in primary antibodies for use in research. It is our goal to continue to grow the Company and create value for all of our stakeholders. We have always delivered on our promises and we will continue to focus on understanding our customers, delivering high quality products, and being the innovation partner of choice for the researchers we serve globally.

About Abcam

Abcam is a producer and marketer of high quality protein research tools. These tools enable life scientists to analyse components of living cells at the molecular level which is essential in a wide range of fields including drug discovery, diagnostics, and basic research.

Read more +

Abcam Products

As an innovator in reagents and tools, Abcam offers highly validated binders and assays to address important targets in critical biological pathways.

Read more +

Investor Information

Abcam is listed on the AIM market of the London Stock Exchange under the ticker ABC, and our investors' centre includes a range of information on our company, including our news, financial reports and investor contacts

Read more +

Abcam News

We provide updates on our commercial and financial progress through regular press releases which can be accessed through the Company's media centre.

Read more +